Naviscan, Inc., the leader in Molecular Breast Imaging (MBI), today announced that Paul J. Mirabella, President and Chief Executive Officer, will be presenting a corporate update at the 4th Annual BIOCOM Investor Conference on October 27, 2009 at 1:00 p.m. being held at Hyatt Regency in La Jolla, California.
The presentation will include a summary of a 388-patient, NIH-sponsored clinical trial comparing their high-resolution breast PET system, Positron Emission Mammography (PEM) scanner, to breast Magnetic Resonance (MR).
"These exciting results, especially during Breast Cancer Awareness Month, will be welcomed news by patients and physicians as a new and effective tool in management of the breast cancer patient," said Mirabella.
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels